Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals

An update from Molecular Partners ( (MOLN) ) is now available.

At its Annual General Meeting held on April 14, 2026, Molecular Partners shareholders elected Clare Fisher to the Board of Directors, reinforcing the company’s business development expertise as it advances its DARPin-based oncology pipeline. Fisher, a seasoned dealmaker currently serving as SVP for Global Business Development and M&A at BeOne Medicines, brings more than two decades of healthcare leadership across corporate development, M&A and strategic roles at major biotech and pharma groups.

Shareholders also approved all board proposals, including the 2025 IFRS financial statements, the compensation report, and a move to carry forward – rather than offset – the 2025 net loss of CHF 57.9 million, lifting total accumulated losses to CHF 257.3 million. The meeting confirmed the re-election of all other directors, with Bill Burns remaining as chairman, refreshed the Nomination and Compensation Committee following the departure of long-serving director Steven H. Holtzman, reappointed KPMG as auditor for 2026, and endorsed binding pay resolutions for the board and management, signaling continued investor backing despite ongoing losses.

The most recent analyst rating on (MOLN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Spark’s Take on MOLN Stock

According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.

The score is weighed down primarily by collapsing revenue and persistent cash burn (weak financial performance), with additional pressure from negative technical momentum (below key moving averages with negative MACD). Valuation is also constrained by losses (negative P/E) and no dividend support.

To see Spark’s full report on MOLN stock, click here.

More about Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company pioneering a novel class of custom-built protein drugs known as DARPin therapeutics to tackle medical challenges that are hard to address with existing modalities. The company is focused on oncology, developing targeted radiopharmaceuticals and next-generation immune cell engagers through proprietary programs and partnerships, with operations in Zurich, Switzerland, and Concord, Mass., U.S.

Average Trading Volume: 4,490

Technical Sentiment Signal: Sell

Current Market Cap: $174.2M

Find detailed analytics on MOLN stock on TipRanks’ Stock Analysis page.